Preclinical models of autoimmune diseases and cancer have demonstrated promising results in blocking the TNFSF15-DR3 pathway, indicating that targeting TNFSF15 could potentially mitigate abnormal immune responses and alleviate inflammation. This evidence concerns the gene TNFSF15 and cancer.